Pomegranate Fruit Extract Impairs Invasion and Motility in Human Breast Cancer

Integrative Cancer Therapies

Volumn 8, Issue 3, 2009, Pages 242-253

  Khan, Gazala N ^a   Gorin, Michael A ^a   Rosenthal, Devin ^a   Pan, Quintin ^a   Bao, Li Wei ^a   Wu, Zhi Fen ^a   Newman, Robert A ^b,c   Pawlus, Alison D ^b   Yang, Peiying ^b   Lansky, Ephraim P ^c   Merajver, Sofia D ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Punisyn Pharmaceuticals   (Israel)

Author keywords

Breast cancer; Cancer prevention; In vitro studies; Punica granatum

Indexed keywords

I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLYPHENOL; POMEGRANATE EXTRACT; RHO FACTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC PROTEIN; UNCLASSIFIED DRUG; WONDERFUL POMEGRANATE PRODUCTS;

ARTICLE; BREAST CANCER; CANCER INVASION; CANCER PREVENTION; CELL INVASION; CELL MOTILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MEDICINAL PLANT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DINOPROSTONE; FEMALE; FRUIT; GENE EXPRESSION; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; LEUKOTRIENE B4; NEOPLASM INVASIVENESS; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; PHYTOTHERAPY; PLANT EXTRACTS; PUNICACEAE; RHO GTP-BINDING PROTEINS; RHOA GTP-BINDING PROTEIN; TRANSCRIPTION FACTOR RELA;

EID: 70350035746     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735409341405     Document Type: Article

References (72)

1. Fisher B., Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005 ; 97: 1652-1662. (Pubitemid 41672231)
2. Cummings SR, Eckert S., Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999 ; 281: 2189-2197.
3. Yang CS, Landau JM, Huang MT, Newmark HL Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr. 2001 ; 21: 381-406.
4. Narayanan BA, Geoffroy O., Willingham MC, Re GG, Nixon DW p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett. 1999 ; 136: 215-221.
5. Waladkhani AR, Clemens MR Effect of dietary phytochemicals on cancer development (review). Int J Mol Med. 1998 ; 1: 747-753.
6. Mehta R., Lansky EP Breast cancer chemopreventive properties of pomegranate (Punica granatum) fruit extracts in a mouse mammary organ culture. Eur J Cancer Prev. 2004 ; 13: 345-348.
7. Lansky EP, Jiang W., Mo H., et al. Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs. 2005 ; 23: 11-20.
8. Afaq F., Malik A., Syed D., Maes D., Matsui MS, Mukhtar H. Pomegranate fruit extract modulates UV-B-mediated phosphorylation of mitogen-activated protein kinases and activation of nuclear factor kappa B in normal human epidermal keratinocytes paragraph sign. Photochem Photobiol. 2005 ; 81: 38-45.
9. Afaq F., Saleem M., Krueger CG, Reed JD, Mukhtar H. Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice. Int J Cancer. 2005 ; 113: 423-433.
10. Pantuck AJ, Leppert JT, Zomorodian N., et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006 ; 12: 4018-4026.
11. Biswas DK, Shi Q., Baily S., et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A. 2004 ; 101: 10137-10142.
12. Khan N., Hadi N., Afaq F., Syed DN, Kweon MH, Mukhtar H. Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis. 2007 ; 28: 163-173.
13. Schubert SY, Lansky EP, Neeman I. Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. J Ethnopharmacol. 1999 ; 66: 11-17.
14. Neve RM, Chin K., Fridlyand J., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006 ; 10: 515-527.
15. Kempen EC, Yang P., Felix E., Madden T., Newman RA Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Biochem. 2001 ; 297: 183-190.
16. Kim JH, Na HK, Pak YK, et al. Roles of ERK and p38 mitogen-activated protein kinases in phorbol ester-induced NF-kappaB activation and COX-2 expression in human breast epithelial cells. Chem Biol Interact. 2008 ; 171: 133-141.
17. Aggarwal BB, Takada Y., Shishodia S., et al. Nuclear transcription factor NF-kappa B: role in biology and medicine. Indian J Exp Biol. 2004 ; 42: 341-353.
18. Shishodia S., Aggarwal BB Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. Cancer Treat Res. 2004 ; 119: 139-173.
19. Streicher KL, Willmarth NE, Garcia J., Boerner JL, Dewey TG, Ethier SP Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells. Mol Cancer Res. 2007 ; 5: 847-861.
20. Pan Q., Bao LW, Merajver SD Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res. 2003 ; 1: 701-706.
21. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996 ; 14: 649-683. (Pubitemid 26130197)
22. Israel A. A role for phosphorylation and degradation in the control of NF-kappa B activity. Trends Genet. 1995 ; 11: 203-205.
23. Kessler DJ, Duyao MP, Spicer DB, Sonenshein GE NF-kappa B-like factors mediate interleukin 1 induction of c-myc gene transcription in fibroblasts. J Exp Med. 1992 ; 176: 787-792.
24. Fujimoto K., Yasuda H., Sato Y., Yamamoto K. A role for phosphorylation in the proteolytic processing of the human NF-kappa B1 precursor. Gene. 1995 ; 165: 183-189.
25. Franco AV, Zhang XD, Van Berkel E., et al. The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol. 2001 ; 166: 5337-5345.
26. Milligan SA, Nopajaroonsri C. Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro. Anticancer Res. 2001 ; 21: 39-44.
27. Perkins ND The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci. 2000 ; 25: 434-440.
28. Jo H., Zhang R., Zhang H., et al. NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene. 2000 ; 19: 841-849.
29. Herrmann JL, Beham AW, Sarkiss M., et al. Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway. Exp Cell Res. 1997 ; 237: 101-109.
30. Sonenshein GE Rel/NF-kappa B transcription factors and the control of apoptosis. Semin Cancer Biol. 1997 ; 8: 113-119.
31. Siebenlist U. NF kappa B/I kappa B proteins. Their role in cell growth, differentiation and development. Biochim Biophys Acta. 1997 ; 1332: R7 - R13.
32. Siebenlist U., Franzoso G., Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994 ; 10: 405-455.
33. Walshe JM, Swain SM Clinical aspects of inflammatory breast cancer. Breast Dis. 2005 ; 22: 35-44.
34. Wu M., Merajver SD Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy. Breast Dis. 2005 ; 22: 25-34.
35. van Golen KL Inflammatory breast cancer: relationship between growth factor signaling and motility in aggressive cancers. Breast Cancer Res. 2003 ; 5: 174-179.
36. Kleer CG, van Golen KL, Merajver SD Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2000 ; 2: 423-429.
37. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res. 2003 ; 5: 31-36.
38. Wu M., Wu ZF, Kumar-Sinha C., Chinnaiyan A., Merajver SD RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res Treat. 2004 ; 84: 3-12.
39. Kleer CG, Griffith KA, Sabel MS, et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat. 2005 ; 93: 101-110.
40. Kleer CG, Zhang Y., Pan Q., et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res. 2004 ; 6: R110 - R115.
41. van Golen KL, Bao LW, Pan Q., Miller FR, Wu ZF, Merajver SD Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metastasis. 2002 ; 19: 301-311.
42. Kleer CG, van Golen KL, Zhang Y., Wu ZF, Rubin MA, Merajver SD Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol. 2002 ; 160: 579-584.
43. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000 ; 60: 5832-5838.
44. Segain JP, Raingeard de la Bletiere D., Sauzeau V., et al. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohnĝ€™s disease and experimental colitis. Gastroenterology. 2003 ; 124: 1180-1187.
45. Greten FR, Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004 ; 206: 193-199.
46. Chen LW, Egan L., Li ZW, Greten FR, Kagnoff MF, Karin M. The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med. 2003 ; 9: 575-581.
47. Karin M., Cao Y., Greten FR, Li ZW NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002 ; 2: 301-310.
48. Tsatsanis C., Androulidaki A., Venihaki M., Margioris AN Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 2006 ; 38: 1654-1661.
49. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004 ; 75: 639-653.
50. Wu CY, Wang CJ, Tseng CC, et al. Helicobacter pylori promote gastric cancer cells invasion through a NF-kappaB and COX-2-mediated pathway. World J Gastroenterol. 2005 ; 11: 3197-3203.
51. Kuo SH, Chen LT, Yeh KH, et al. Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas. J Clin Oncol. 2004 ; 22: 3491-3497.
52. Sun Z., Sood S., Li N., et al. Involvement of the 5-lipoxygenase/ leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a] anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors. Carcinogenesis. 2006 ; 27: 1902-1908.
53. Sun Z., Sood S., Li N., et al. Chemoprevention of 7,12-dimethylbenz[a] anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinases. Oral Oncol. 2008 ; 44: 652-657.
54. Natarajan R., Nadler J. Role of lipoxygenases in breast cancer. Front Biosci. 1998 ; 3: E81 - E88.
55. Nie D., Krishnamoorthy S., Jin R., et al. Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. J Biol Chem. 2006 ; 281: 18601-18609.
56. Nony PA, Kennett SB, Glasgow WC, Olden K., Roberts JD 15S-Lipoxygenase-2 mediates arachidonic acid-stimulated adhesion of human breast carcinoma cells through the activation of TAK1, MKK6, and p38 MAPK. J Biol Chem. 2005 ; 280: 31413-31419.
57. Virgili F., Kobuchi H., Packer L. Procyanidins extracted from Pinus maritima (Pycnogenol): scavengers of free radical species and modulators of nitrogen monoxide metabolism in activated murine RAW 264.7 macrophages. Free Radic Biol Med. 1998 ; 24: 1120-1129.
58. Badmaev V., Kozlowski PB, Schuller-Levis GB, Wisniewski HM The therapeutic effect of an herbal formula Badmaev 28 (padma 28) on experimental allergic encephalomyelitis (EAE) in SJL/J mice. Phytother Res. 1999 ; 13: 218-221.
59. Calder PC Polyunsaturated fatty acids, inflammation, and immunity. Lipids. 2001 ; 36: 1007-1024.
60. Repetto MG, Llesuy SF Antioxidant properties of natural compounds used in popular medicine for gastric ulcers. Braz J Med Biol Res. 2002 ; 35: 523-534.
61. Gatto B. Biologics targeted at TNF: design, production and challenges. Reumatismo. 2006 ; 58: 94-103.
62. Sharma S., Chopra K., Kulkarni SK, Agrewala JN Resveratrol and curcumin suppress immune response through CD28/ CTLA-4 and CD80 co-stimulatory pathway. Clin Exp Immunol. 2007 ; 147: 155-163.
63. Nonn L., Duong D., Peehl DM Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis. 2007 ; 28: 1188-1196.
64. Lao CD, Demierre MF, Sondak VK Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert Rev Anticancer Ther. 2006 ; 6: 1559-1568.
65. Bemis DL, Katz AE, Buttyan R. Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs. 2006 ; 15: 1191-1200.
66. Dulak J. Nutraceuticals as anti-angiogenic agents: hopes and reality. J Physiol Pharmacol. 2005 ; 56 (suppl 1). 51-67.
67. Liontas A., Yeger H. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. Anticancer Res. 2004 ; 24: 987-998.
68. Deeb D., Xu YX, Jiang H., et al. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther. 2003 ; 2: 95-103.
69. Hong MY, Seeram NP, Heber D. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. J Nutr Biochem. 2008 ; 19: 848-855.
70. Adams LS, Seeram NP, Aggarwal BB, Takada Y., Sand D., Heber D. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem. 2006 ; 54: 980-985.
71. Seeram NP, Adams LS, Henning SM, et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem. 2005 ; 16: 360-367.
72. Cammarano MS, Minden A. Dbl and the Rho GTPases activate NF kappa B by I kappa B kinase (IKK)-dependent and IKK-independent pathways. J Biol Chem. 2001 ; 276: 25876-25882.